Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 7 |
| List of Tables | 7 | 1 |
| List of Figures | 8 | 1 |
| Introduction | 9 | 1 |
| Global Markets Direct Report Coverage | 9 | 1 |
| Toll Like Receptor 4 (CD284 or TLR4) Overview | 10 | 1 |
| Therapeutics Development | 11 | 5 |
| Toll Like Receptor 4 (CD284 or TLR4) Products under Development by Stage of Development | 11 | 1 |
| Toll Like Receptor 4 (CD284 or TLR4) Products under Development by Therapy Area | 12 | 1 |
| Toll Like Receptor 4 (CD284 or TLR4) Products under Development by Indication | 13 | 3 |
| Toll Like Receptor 4 (CD284 or TLR4) Pipeline Products Glance | 16 | 2 |
| Late Stage Products | 16 | 1 |
| Early Stage Products | 17 | 1 |
| Toll Like Receptor 4 (CD284 or TLR4) Products under Development by Companies | 18 | 5 |
| Toll Like Receptor 4 (CD284 or TLR4) Products under Development by Universities/Institutes | 23 | 2 |
| Toll Like Receptor 4 (CD284 or TLR4) Therapeutics Assessment | 25 | 7 |
| Assessment by Monotherapy/Combination Products | 25 | 1 |
| Assessment by Mechanism of Action | 26 | 2 |
| Assessment by Route of Administration | 28 | 2 |
| Assessment by Molecule Type | 30 | 2 |
| Toll Like Receptor 4 (CD284 or TLR4) Companies Involved in Therapeutics Development | 32 | 15 |
| Batu Biologics, Inc. | 32 | 1 |
| BioLineRx, Ltd. | 33 | 1 |
| Biomedica Management Corporation | 34 | 1 |
| Eisai Co., Ltd. | 35 | 1 |
| eTheRNA Immunotherapies NV | 36 | 1 |
| Formune S.L. | 37 | 1 |
| GlaxoSmithKline Plc | 38 | 1 |
| Harbor Therapeutics, Inc. | 39 | 1 |
| Immune Design Corp. | 40 | 1 |
| Immunovo BV | 41 | 1 |
| Kyorin Pharmaceutical Co., Ltd. | 42 | 1 |
| NovImmune SA | 43 | 1 |
| Reliance Life Sciences Pvt. Ltd. | 44 | 1 |
| TaiwanJ Pharmaceuticals Co., Ltd. | 45 | 1 |
| Vascular Biogenics Ltd. | 46 | 1 |
| Toll Like Receptor 4 (CD284 or TLR4) Drug Profiles | 47 | 53 |
| ApTLR-4FT Drug Profile | 47 | 1 |
| BL-1110 Drug Profile | 48 | 2 |
| C-34 Drug Profile | 50 | 1 |
| CRX-526 Drug Profile | 51 | 1 |
| DMT-210 Drug Profile | 52 | 1 |
| EDA-GP120 Drug Profile | 53 | 1 |
| EDA-HPVE7 Drug Profile | 54 | 1 |
| EDA-NS3 Drug Profile | 55 | 1 |
| EDA-TRP2 Drug Profile | 56 | 1 |
| eritoran tetrasodium Drug Profile | 57 | 2 |
| G-100 Drug Profile | 59 | 3 |
| Glyco-23 Drug Profile | 62 | 1 |
| GSK-1795091 Drug Profile | 63 | 1 |
| HE-3286 Drug Profile | 64 | 3 |
| hp-91 Drug Profile | 67 | 1 |
| ibudilast Drug Profile | 68 | 8 |
| JKB-117 Drug Profile | 76 | 1 |
| JKB-119 Drug Profile | 77 | 1 |
| JKB-121 Drug Profile | 78 | 1 |
| naltrexone hydrochloride Drug Profile | 79 | 2 |
| NI-0101 Drug Profile | 81 | 1 |
| Oligonucleotide to Activate CD40L, CD70 and TLR-4 for Oncology and Infectious Diseases Drug Profile | 82 | 1 |
| P-13 Drug Profile | 83 | 1 |
| P-16 Drug Profile | 84 | 1 |
| P-7 Drug Profile | 85 | 1 |
| P-MAPA Drug Profile | 86 | 2 |
| PEPA-10 Drug Profile | 88 | 1 |
| RSCL-0520 Drug Profile | 89 | 1 |
| Small Molecules to Antagonize TLR-4 for CNS Disorders Drug Profile | 90 | 1 |
| Small Molecules to Antagonize TLR2 and TLR4 for Immune inflammatory Diseases Drug Profile | 91 | 1 |
| Small Molecules to Antagonize TLR4 for Acute Lung Injury and Bacterial Sepsis Drug Profile | 92 | 1 |
| Small Molecules to Antagonize Toll-Like Receptor 4 for Oncology and Autoimmune Disorders Drug Profile | 93 | 1 |
| Synthetic Peptide to Antagonize TLR-4 for Oncology, Immunology and Infectious Disease Drug Profile | 94 | 1 |
| VB-201 Drug Profile | 95 | 3 |
| VB-3323 Drug Profile | 98 | 1 |
| VB-703 Drug Profile | 99 | 1 |
| Toll Like Receptor 4 (CD284 or TLR4) Dormant Projects | 100 | 4 |
| Toll Like Receptor 4 (CD284 or TLR4) Discontinued Products | 104 | 1 |
| Toll Like Receptor 4 (CD284 or TLR4) Featured News &Press Releases | 105 | 10 |
| Jun 08, 2016: Immune Design Announces Updated Results For Its Immuno-oncology Product Candidate G100 At ASCO | 105 | 1 |
| May 25, 2016: MediciNova Announces Additional Results from the Completed Trial of MN-166 (ibudilast) in Alcohol Dependence to be Presented at the 39th Annual Scientific Meeting of the Research Society on Alcoholism in New Orleans, Louisiana | 105 | 1 |
| May 16, 2016: Dermata Therapeutics Announces Initiation of Phase 1 Pharmacokinetic Study | 106 | 1 |
| Apr 21, 2016: Immune Design Announces Presentations on G-100 at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting | 106 | 1 |
| Apr 20, 2016: MediciNova Announces Interim Data from Clinical Trial of MN-166 (ibudilast) in ALS Presented at the American Academy of Neurology (AAN) 68th Annual Meeting in Vancouver, Canada | 107 | 1 |
| Apr 20, 2016: Immune Design Presents New Preclinical Data on Advances of Two Separate Intratumoral Approaches at the American Association for Cancer Research (AACR) Annual Meeting 2016 | 108 | 1 |
| Mar 30, 2016: MediciNova Announces Publication of Positive Findings from Completed Phase 1b Clinical Trial of MN-166 (ibudilast) in Methamphetamine Dependence | 109 | 1 |
| Mar 22, 2016: FDA Grants Fast Track Designation for MediciNovas MN-166 (ibudilast) for Progressive Multiple Sclerosis | 110 | 1 |
| Mar 07, 2016: MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Amyotrophic Lateral Sclerosis | 111 | 1 |
| Mar 06, 2016: MediciNova Announces Positive Findings From a Completed Phase 2 Trial of MN-166 (ibudilast) in Opioid Dependence at the Behavior, Biology and Chemistry: Translational Research in Addiction Meeting in San Antonio, Texas | 111 | 1 |
| Feb 22, 2016: MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Dual Presentation at the American Academy of Neurology 68th Annual Meeting in Vancouver, Canada | 112 | 1 |
| Feb 11, 2016: MediciNova Announces Presentation Regarding MN-166 (ibudilast) and Methamphetamine Dependence at the Behavior, Biology and Chemistry Annual Meeting and Symposium in San Antonio, Texas | 113 | 1 |
| Feb 09, 2016: Immune Design Announces Data From Phase 1 Clinical Trial of G100 | 113 | 1 |
| Feb 07, 2016: MediciNova Announces Presentation of Data From the Completed Phase 2 Trial of MN-166 (ibudilast) in Opioid Dependence at the Behavior, Biology and Chemistry Annual Meeting and Symposium in San Antonio, Texas | 113 | 1 |
| Jan 18, 2016: FDA Grants Rare Pediatric Disease Designation to MediciNova s MN-166 (ibudilast) for the Treatment of Krabbe Disease | 114 | 1 |
| Appendix | 115 | 2 |
| Methodology | 115 | 1 |
| Coverage | 115 | 1 |
| Secondary Research | 115 | 1 |
| Primary Research | 115 | 1 |
| Expert Panel Validation | 115 | 1 |
| Contact Us | 115 | 1 |
| Disclaimer | 116 | 1 |